COLLEEN MOORE: Open Payments
NPI 1720569593 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,399 in 125 payments from 17 companies in 2025. Trend: 2023 $1,342 · 2024 $2,711 · 2025 $3,399
Food & beverage: $3,288Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $598 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $434 |
| Teva Pharmaceuticals USA, Inc. | 13 | $342 |
| Lundbeck LLC | 12 | $299 |
| Lilly USA, LLC | 13 | $294 |
| Eisai Inc. | 8 | $291 |
| Merz Pharmaceuticals, LLC | 8 | $204 |
| Novo Nordisk Inc | 2 | $161 |
| PFIZER INC. | 6 | $149 |
| Neurocrine BioSciences, Inc. | 5 | $146 |
Products named: CAPLYTA, Leqembi, KISUNLA, REXULTI, AUSTEDO XR, UBRELVY, BOTOX, NURTEC ODT.
Industry payments across WA — which companies pay providers there.
